Search

Displaying results 3021 - 3030 of 8517 in total
  1. Drug

    Levmetamfetamine

    go.drugbank.com/drugs/DB09571
    Approved

    Levomethamphetamine, the L-enantiomer of methamphetamine is a sympathomimetic vasoconstrictor used in some over-the-counter (OTC) nasal decongestant inhalers in the United States.

  2. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).

  3. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  4. Drug

    CRx-401

    go.drugbank.com/drugs/DB05775
    Experimental

    has proven to be well tolerated in clinical trials. … In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose

  5. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as

  6. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    growth factor (VEGF), basic fibroblast growth factor (bFGF), as well as other pro-angiogenic growth factors. … The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  7. Drug

    Synthetic Conjugated Estrogens, B

    go.drugbank.com/drugs/DB09318
    Approved

    Available as either "Synthetic Conjugated Estrogens, A" containing 9 estrogen derivatives (available as Cenestin) or as "Synthetic Conjugated Estrogens, B" containing 10 estrogen derivatives (available … as Enjuvia), these products are isolated as precursors from yam or soy plants and then chemically modified to mimic the products available in their naturally occurring form.

  8. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … It is available commercially as the monoclonal antibody portion of the antibody-drug conjugate [brentuximab vedotin].

  9. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    [L47153,L47158] Somatrogon is available as a once-weekly subcutaneous injection.[L39080,L47153] … [A241485] Somatrogon was produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology.

  10. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    As adefovir is poorly absorbed and associated with a high level of nephrotoxicity, pradefovir mesilate was designed to specifically target the liver and reduce risks to external tissue, especially the … Pradefovir mesilate (previously known as MB-06886, Hepavir B and remofovir mesylate) is an orally administered small molecule compound that belongs to a novel series of phosphate and phosphonate prodrugs